Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for NovaBay Pharmaceuticals (NBY) over the last 16 years, with Q3 2025 value amounting to $394000.0.

  • NovaBay Pharmaceuticals' Other Non-Current Assets fell 2040.4% to $394000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $394000.0, marking a year-over-year decrease of 2040.4%. This contributed to the annual value of $1.2 million for FY2024, which is 5483.52% down from last year.
  • Per NovaBay Pharmaceuticals' latest filing, its Other Non-Current Assets stood at $394000.0 for Q3 2025, which was down 2040.4% from $479000.0 recorded in Q2 2025.
  • In the past 5 years, NovaBay Pharmaceuticals' Other Non-Current Assets ranged from a high of $2.7 million in Q4 2023 and a low of $153000.0 during Q3 2022
  • Over the past 5 years, NovaBay Pharmaceuticals' median Other Non-Current Assets value was $477000.0 (recorded in 2024), while the average stood at $584210.5.
  • As far as peak fluctuations go, NovaBay Pharmaceuticals' Other Non-Current Assets tumbled by 6785.71% in 2022, and later skyrocketed by 45828.22% in 2023.
  • NovaBay Pharmaceuticals' Other Non-Current Assets (Quarter) stood at $476000.0 in 2021, then increased by 2.73% to $489000.0 in 2022, then soared by 458.28% to $2.7 million in 2023, then tumbled by 54.84% to $1.2 million in 2024, then crashed by 68.05% to $394000.0 in 2025.
  • Its Other Non-Current Assets was $394000.0 in Q3 2025, compared to $479000.0 in Q2 2025 and $479000.0 in Q1 2025.